Filing Details
- Accession Number:
- 0000950170-25-084556
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-10 19:00:05
- Reporting Period:
- 2025-06-09
- Filing Date:
- 2025-06-10
- Accepted Time:
- 2025-06-10 19:00:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1579428 | Axsome Therapeutics Inc. | AXSM | Pharmaceutical Preparations (2834) | 454241907 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1805812 | L. Mark Jacobson | C/O Axsome Therapeutics, Inc. One World Trade Center, 29Th Floor New York NY 10007 | Chief Operating Officer | No | No | No | No |
Transaction Summary
| Sold: | 25,000 shares | Avg. Price: $110.44 | Total Value: $2,761,000.00 |
| Number of Shares After Transactions: | 5,783 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-06-09 | 25,000 | $8.02 | 30,783 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-06-09 | 25,000 | $110.44 | 5,783 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-06-09 | 25,000 | $0.00 | 25,000 | $8.02 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2017-05-27 | 2026-05-27 | No | 4 | M | Direct |
Footnotes
- Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.
- Such transaction was pursuant to a pre-approved 10b5-1 plan.
- Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24.
Billionaire Hedge Funds
